Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback